Mechanism of Action of Risdiplam

  Matthew Klein, MD, Chief Development Officer at PTC Therapeutics, explains the mechanism of action of risdiplam (Evrysdi), an approved daily therapy for spinal muscular atrophy (SMA) in patients 2 months and older. SMA is a rare inherited neuromuscular disorder...